James Phillips
Chief Executive Officer presso Paion Deutschland GmbH
Profilo
James Neil Phillips is the founder of Talisker Pharma Ltd.
which was founded in 2004.
He held the position of Chief Executive Officer from 2004 to 2006.
Currently, he holds the position of Non-Executive Director at Insense Ltd.
since 2011, Co-Managing Director at Paion Deutschland GmbH, and Non-Executive Director at Aplagon Oy.
He was also the Chief Executive Officer & Executive Director at Biodexa Pharmaceuticals Plc from 2013 to 2018.
Additionally, he held several other positions such as Non-Executive Chairman at Prosonix Ltd.
from 2007 to 2012, Director at CRF Box Oy, Director at Healthcare Brands International Ltd.
from 2011 to 2013, Director at West Sussex Health Authority, Director at Lifegard Technologies, Director at Diabetology Ltd., Director at EUSA Pharma SAS, and Independent Director at Herantis Pharma Oyj.
Dr. Phillips also worked as a Senior Executive at Johnson & Johnson, Novartis AG, and Jazz Pharmaceuticals UK Ltd.
He was the President at Eusa Pharma Europe Ltd.
from 2006 to 2007 and Senior Vice President-Corporate Development at EUSA Pharma, Inc. Dr. Phillips holds an MBA degree from Bayes Business School.
Posizioni attive di James Phillips
| Società | Posizione | Inizio |
|---|---|---|
Insense Ltd.
 Insense Ltd. BiotechnologyHealth Technology Insense Ltd. develops products for treatment of wounds and skin conditions. Its development activity is concentrated on dermatology products for both professional and consumer applications. The company was founded in 2001 by Paul James Davis and is headquartered in Bedford, the United Kingdom. | Director/Board Member | 01/01/2011 |
Aplagon Oy
 Aplagon Oy Financial ConglomeratesFinance Aplagon Oy provides pharmaceutical discovery and development services. It develops locally acting antithrombotic products (APACs). The company was founded by Riitta Lassila and Yrjo Sakari Lassila in 2009 and is headquartered in Helsinki, Finland. | Director/Board Member | - |
Paion Deutschland GmbH
 Paion Deutschland GmbH BiotechnologyHealth Technology Paion Deutschland GmbH engages in the development of pharmaceutical products. The company is headquartered in Aachen, Germany. | Chief Executive Officer | - |
Precedenti posizioni note di James Phillips
| Società | Posizione | Fine |
|---|---|---|
| PAION AG | Chief Executive Officer | 30/11/2022 |
ImevaX GmbH
 ImevaX GmbH BiotechnologyHealth Technology ImevaX GmbH develops vaccines against pathogens of chronic infectious diseases, especially helicobacter pylori. It offers diagnostic and therapeutic methods for bacterial agents. The company was founded by Markus Gerhard in 2014 and is headquartered in Munich, Germany. | Chief Executive Officer | 01/10/2019 |
| BIODEXA PHARMACEUTICALS PLC | Chief Executive Officer | 31/05/2018 |
Healthcare Brands International Ltd.
 Healthcare Brands International Ltd. Pharmaceuticals: MajorHealth Technology Healthcare Brands International (HBI) is a new company, established in the UK in October 2006, and participating primarily in the growing market of OTC Medicines. The company is committed to acquiring, developing and investing in differentiated healthcare products. In short it will translate innovative science into meaningful consumer brands. Funded with over £100 million of venture capital from leading international venture capital investors, the company is a team of experienced OTC blue chip business professionals with an unrivalled network of partners and contacts around the world (with particular strength in Europe). It brings core skills in consumer marketing and brand development and combine with partners providing in-market operational and regulatory expertise. It will focus on innovative products with meaningful and substantiated differentiation that meet a relevant and yet unmet or only partially met consumer need and thereby help grow the overall self-medication market. | Director/Board Member | 01/04/2013 |
Jazz Pharmaceuticals UK Ltd.
 Jazz Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom. | President | - |
Formazione di James Phillips
| Bayes Business School | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 6 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| PAION AG | Health Technology |
| NOVARTIS AG | Health Technology |
| BOTANIX PHARMACEUTICALS LIMITED | Health Technology |
| HERANTIS PHARMA OYJ | Health Technology |
| BIODEXA PHARMACEUTICALS PLC | Health Technology |
| Aziende private | 17 |
|---|---|
Insense Ltd.
Insense Ltd. BiotechnologyHealth Technology Insense Ltd. develops products for treatment of wounds and skin conditions. Its development activity is concentrated on dermatology products for both professional and consumer applications. The company was founded in 2001 by Paul James Davis and is headquartered in Bedford, the United Kingdom. | Health Technology |
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Health Technology |
CRF Box Oy
 CRF Box Oy Packaged SoftwareTechnology Services CRF Box Oy operates as a software company. It creates electronic clinical outcome assessment (eCOA) solutions. The firm offers project management, scientific support, collaborative design, program management, localization, training and eLearning, and logistic services. The company was founded in 2000 and is headquartered in Helsinki, Finland. | Technology Services |
Healthcare Brands International Ltd.
Healthcare Brands International Ltd. Pharmaceuticals: MajorHealth Technology Healthcare Brands International (HBI) is a new company, established in the UK in October 2006, and participating primarily in the growing market of OTC Medicines. The company is committed to acquiring, developing and investing in differentiated healthcare products. In short it will translate innovative science into meaningful consumer brands. Funded with over £100 million of venture capital from leading international venture capital investors, the company is a team of experienced OTC blue chip business professionals with an unrivalled network of partners and contacts around the world (with particular strength in Europe). It brings core skills in consumer marketing and brand development and combine with partners providing in-market operational and regulatory expertise. It will focus on innovative products with meaningful and substantiated differentiation that meet a relevant and yet unmet or only partially met consumer need and thereby help grow the overall self-medication market. | Health Technology |
| Talisker Pharma Ltd. | |
| West Sussex Health Authority | |
| Lifegard Technologies | |
Diabetology Ltd.
 Diabetology Ltd. Miscellaneous Commercial ServicesCommercial Services Diabetology Ltd. offers biopharmaceutical research and development services. It develops Capsulin and novel Axcess oral form of insulin for diabetics that incorporates absorption enhancers with unmodified bioactive in a convenient encapsulated form. The company was founded by Roger New and Glen Travers in 2002 and is headquartered in St. Helier, Jersey. | Commercial Services |
Prosonix Ltd.
 Prosonix Ltd. Pharmaceuticals: MajorHealth Technology Prosonix Ltd. engages in the provision of inhaled respiratory medicines. The company was founded by Andre James Bush and David Hipkiss in 2006 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Vantia Ltd.
 Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Commercial Services |
EUSA Pharma SAS
 EUSA Pharma SAS BiotechnologyHealth Technology EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France. | Health Technology |
Jazz Pharmaceuticals UK Ltd.
Jazz Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom. | Health Technology |
Paion Deutschland GmbH
Paion Deutschland GmbH BiotechnologyHealth Technology Paion Deutschland GmbH engages in the development of pharmaceutical products. The company is headquartered in Aachen, Germany. | Health Technology |
Midatech Ltd.
 Midatech Ltd. BiotechnologyHealth Technology Midatech Ltd. engages in research and experimental development on biotechnology services. The company is headquartered in Abingdon, the United Kingdom. | Health Technology |
Aplagon Oy
Aplagon Oy Financial ConglomeratesFinance Aplagon Oy provides pharmaceutical discovery and development services. It develops locally acting antithrombotic products (APACs). The company was founded by Riitta Lassila and Yrjo Sakari Lassila in 2009 and is headquartered in Helsinki, Finland. | Finance |
ImevaX GmbH
ImevaX GmbH BiotechnologyHealth Technology ImevaX GmbH develops vaccines against pathogens of chronic infectious diseases, especially helicobacter pylori. It offers diagnostic and therapeutic methods for bacterial agents. The company was founded by Markus Gerhard in 2014 and is headquartered in Munich, Germany. | Health Technology |
| Eusa Pharma Europe Ltd. |
- Borsa valori
- Insiders
- James Phillips
